Perfusion Medical has been awarded an $1.8 million AFWERX Phase II STTR to continue development of the hemorrhagic shock treatment drug, PM-208, which was invented at Virginia Commonwealth University. This grant funds support work on developing the drug in a smaller package which is necessary for use in military field environments.

As the innovation arm of the Department of the Air Force and powered by the Air Force Research Laboratory (AFRL), AFWERX brings cutting edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX teams internationally across academia, industry, and government to develop technology, expand talent and transition dual-use capabilities.